5,63 $
6,32 % gestern
Nasdaq, 3. Oktober, 22:04 Uhr
ISIN
US83548R1059
Symbol
SONN
Berichte

Sonnet BioTherapeutics Holdings Inc Aktie News

Neutral
GlobeNewsWire
15 Tage alt
PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that Raghu Rao, Interim Chief Executive Officer of Sonnet, will present on Thursday, September 25, 2025 at 9:40 AM PT at the MedInvest Biotech...
Neutral
GlobeNewsWire
etwa 2 Monate alt
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
Neutral
GlobeNewsWire
2 Monate alt
Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (Tecentriq ® ) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)
Positiv
Finbold
3 Monate alt
Shares of Sonnet BioTherapeutics (NASDAQ: SONN) soared in pre-market trading on Monday after the company announced a $888 million business combination to pivot into the cryptocurrency sector.
Neutral
Business Wire
3 Monate alt
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN) and Rorschach I LLC is fair to Sonnet shareholders. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company. Halper Sadeh encourages Sonnet shareholders to click here to learn more ...
Neutral
GlobeNewsWire
3 Monate alt
Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury
Neutral
GlobeNewsWire
5 Monate alt
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6 th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA.
Neutral
GlobeNewsWire
6 Monate alt
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen